St Joseph Hospital — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$125,630	5
2024	Research	$105,539	4
2023	Research	$176,737	4
2022	Research	$13,334	5
2021	Research	$11,463	5
2020	Research	$10,301	2
2019	Research	$62,840	4

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $304,343 12 payments
Eli Lilly and Company $150,706 12 payments
Bard Peripheral Vascular, Inc. $41,296 2 payments
Biotronik Inc. $9,500 3 payments

Studies the money was for Research payments · program years 2019–2025

An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $287,016 7 payments
Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $103,960 5 payments
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $33,799 5 payments
Lutonix Av Pas Cl003301 $31,878 1 payment
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer $16,800 1 payment
Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $12,788 1 payment
Bioflow-VII $9,500 3 payments
Aveva Bpv15001 $9,418 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of Lnp023 in Primary Iga Nephropathy Patients $308 2 payments
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages Ib-Iiia, N2 and Selected Iiib (T3n2 Or T4n2) Nsclc With Met Exon 14 Skipping Mutation Or High Met Amplification (Geometry-N) $218 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.